Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

New York, drug distributors reach $1.18 billion opioid settlement as national deal looms

Published 07/20/2021, 09:14 AM
Updated 07/20/2021, 06:05 PM
© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017.  REUTERS/Bryan Woolston

(Removes extra word from name of firm in paragraph 11)

By Brendan Pierson and Nate Raymond

NEW YORK (Reuters) -The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state's attorney general said on Tuesday.

McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH) and AmerisourceBergen (NYSE:ABC) Corp settled as state attorneys general prepare to announce as soon as this week a landmark $26 billion deal with the distributors and drugmaker Johnson & Johnson (NYSE:JNJ) resolving cases nationwide.

The deal with New York Attorney General Letitia James and the populous Long Island counties of Nassau and Suffolk came three weeks into the first jury trial accusing companies of profiting from a flood of addictive painkillers that devastated communities.

"While no amount of money will ever compensate for the millions of addictions, the hundreds of thousands of deaths, or the countless communities decimated by opioids, this money will be vital in preventing any future devastation," James said.

Hunter Shkolnik, a lawyer for Nassau County at the law firm Napoli Shkolnik, said in a statement that unlike the proposed national settlement, the New York deal "is not contingent on the rest of the country or other states joining."

In a joint statement, the distributors called the settlement "an important step toward finalizing a broad settlement with states, counties, and political subdivisions."

'GETTING CLOSE' ON NATIONAL SETTLEMENT

The national settlement is expected to be announced later this week, people familiar with the matter said. Joe Rice, a lead negotiator for lawyers for the cities and counties at Motley Rice, told reporters the parties are "getting close" to finalizing a deal.

State attorneys general from 10 states including Tennessee, Texas, Pennsylvania and North Carolina in a joint statement on Tuesday said their "negotiations are progressing well and potentially nearing their completion."

After the framework is announced, states and their subdivisions will need to decide whether to join the global accord, the sources have said. The ultimate settlement price-tag could fluctuate depending on how many agree to the deal or reject it to pursue litigation on their own.

The settlement also calls the creation of a national clearinghouse of data on opioid shipments operated under the oversight of an independent third-party monitor.

Paul Geller, a lead negotiator for the plaintiffs at Robbins Geller Rudman & Dowd, said that provision would be "transformative" in battling drug oversupply.

Nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019, according to the U.S. Centers for Disease Control and Prevention. The CDC last week said provisional data showed that 2020 was a record year for overall drug overdose deaths with 93,331, up 29% from a year earlier.

REMAINING DEFENDANTS

More than 3,300 cases have been filed largely by states and local governments alleging drugmakers falsely marketed opioid painkillers as safe, and distributors and pharmacies of ignoring red flags that they were being diverted to illegal channels.

The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers - Endo International (NASDAQ:ENDP) Plc, Teva Pharmaceutical Industries (NYSE:TEVA) Ltd and AbbVie Inc (NYSE:ABBV)'s Allergan (NYSE:AGN) unit.

Ahead of the trial, Johnson & Johnson agreed to pay $263 million to resolve the claims by the state and counties. Pharmacy operators Walgreens Boots Alliance (NASDAQ:WBA) Inc, CVS Health Corp (NYSE:CVS), Rite Aid (NYSE:RAD) Corp and Walmart (NYSE:WMT) Inc agreed to settle with the counties for a combined $26 million.

Two other opioid cases are also on trial in West Virginia and California. The companies have denied wrongdoing.

© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017.  REUTERS/Bryan Woolston

James' office said that of the nearly $1.18 billion the distributors agreed to pay, more than $1 billion will go toward addressing the epidemic. The counties have said the money will be used for mental health and addiction programs.

Payments will start in two months and will continue over the next 17 years, James said.

Latest comments

500 thousand deaths from opioid crisis really? 500 thousand died from herion overdoses last year, what's that got to do with prescription pain killers? 500k out of 330 million Americans, is about .001 percent of the population. **** the AG's will deny 99.9 percent of the American population proper pain medication because it negatively affects .001 percent of the public? I'm in chronic pain and pain meds are no longer prescribed, it's like a frigging horror show!
Can we sue China now for ** ***in the US and counting?
guy on the street peddling drugs loses everything, house, car, and goes to jail, guy in a suit peddling drugs looses half their bonus, why aren’t the DEA and FBI seizing their assets?
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.